Evidence map›Paper›PMID 37958671›Full record

ArticleInternational journal of molecular sciences2023

Potential Modifying Effect of the

César A Valdez-Gaxiola, Eric Jonathan Maciel-Cruz, Rubiceli Hernández-Peña, Sofía Dumois-Petersen, Frida Rosales-Leycegui, Martha Patricia Gallegos-Arreola, José Miguel Moreno-Ortiz, Luis E Figuera

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. International journal of molecular sciences · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

César A Valdez-GaxiolaDivisión de Genética, Centro de Investigación Biomédica de Occidente, IMSS, Guadalajara 44340, Jalisco, Mexico.ORCID 0009-0009-6100-093X
Eric Jonathan Maciel-CruzDivisión de Genética, Centro de Investigación Biomédica de Occidente, IMSS, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-6820-9001
Rubiceli Hernández-PeñaDivisión de Genética, Centro de Investigación Biomédica de Occidente, IMSS, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0003-2988-0868
Sofía Dumois-PetersenDivisión de Genética, Centro de Investigación Biomédica de Occidente, IMSS, Guadalajara 44340, Jalisco, Mexico.
Frida Rosales-LeyceguiDivisión de Genética, Centro de Investigación Biomédica de Occidente, IMSS, Guadalajara 44340, Jalisco, Mexico.ORCID 0009-0005-8172-2420
Martha Patricia Gallegos-ArreolaDivisión de Genética, Centro de Investigación Biomédica de Occidente, IMSS, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0003-4539-1693
José Miguel Moreno-OrtizDoctorado en Genética Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
Luis E FigueraDivisión de Genética, Centro de Investigación Biomédica de Occidente, IMSS, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-6096-4579
Universidad de Guadalajara · MXSecretaría de Salud de Jalisco · MX

Funding

HAITI AIDS RESEARCH TRAINING: MODELS TO IMPLEMENTATIONU2RTW006901 · FIC · WEILL MEDICAL COLL OF CORNELL UNIV · PI JOHNSON, WARREN DOUGLAS · 2004 to 2009
$1.1M
FIC NIH HHS R01AG06901
6 · The paper itself

Abstract

In Alzheimer's disease (AD), the age of onset (AoO) exhibits considerable variability, spanning from 40 to 90 years. Specifically, individuals diagnosed with AD and exhibiting symptoms prior to the age of 65 are typically classified as early onset (EOAD) cases. Notably, the apolipoprotein E (APOE) ε4 allele represents the most extensively studied genetic risk factor associated with AD. We clinically characterized and genotyped the

Indexed as

Alzheimer DiseaseAdultAgedAged, 80 and overAge of OnsetAllelesApolipoprotein E4Apolipoproteins EGenotypeHumansMiddle AgedPresenilin-1ApoE protein, humanApolipoprotein E4Apolipoproteins EPresenilin-1PSEN1 protein, humanage of onsetapolipoprotein Eclinical manifestationsearly-onset Alzheimer’s disease

Identifiers

PMID37958671
PMCPMC10648484
OpenAlexW4388097413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.